IGC Pharma, Inc. (India Globalization Capital, Inc.) — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2021. The filing identifies the registrant as India Globalization Capital, Inc. Financial amounts below are in U.S. dollars; figures are in millions unless stated otherwise.
Business context
The company reports two segments: Life Sciences, spanning cannabinoid-focused drug development and wellness products, and Infrastructure, including construction, equipment rental and commodity resale. Management says its focus is on IGC-AD1, an investigational Alzheimer’s drug, and a cannabinoid-based women’s wellness line. Infrastructure operations in India and Hong Kong remained affected by COVID-19 restrictions.
Key financial metrics
| Metric | Three months ended Sept. 30, 2021 | Six months ended Sept. 30, 2021 |
|---|---|---|
| Revenue | $56,000, down 55% year over year | $133,000, down 81% |
| Gross profit | $38,000; approximately 68% gross margin | $64,000; approximately 48% gross margin |
| Operating loss | $4.35 million | $6.54 million |
| Net loss | $4.34 million; $0.09 per share | $6.13 million; $0.13 per share |
| Cash used in operations | $4.15 million for the six months | |
| Cash at period end | $14.40 million | |
| Working capital | $19.69 million at Sept. 30, versus $21.15 million at March 31 |
Cash used in investing was $140,000 and financing provided $4.14 million for the six months. Financing proceeds were primarily from the at-the-market equity offering. Total liabilities were $2.58 million, including approximately $149,000 in loans and $521,000 in operating lease liabilities. The company reported total assets of $33.84 million and stockholders’ equity of $31.26 million.
Material changes versus prior comparable periods
- Quarterly revenue declined from $125,000 to $56,000; six-month revenue fell from $709,000 to $133,000. Life Sciences revenue for the six months dropped to $115,000 from $642,000, while Infrastructure revenue was $18,000 versus $67,000.
- Six-month SG&A rose 82% to $5.89 million. The increase included a roughly $1.7 million provision for inventory reported stolen at a vendor, legal and settlement-related costs, a $125,000 IRS penalty, and higher stock-based compensation and depreciation.
- Six-month R&D expense rose 63% to $720,000, primarily reflecting Alzheimer’s trial and product research costs.
- Other income included $430,000 from forgiveness of a Paycheck Protection Program loan. The company also recorded a $37,000 investment impairment.
- The company raised $4.15 million net through equity issuance during the six months. Common shares outstanding increased to 51.04 million from 47.83 million at March 31, 2021.
Outlook, risks and contingencies
- Management said existing cash and liquidity arrangements should cover working capital, operations, capital needs and clinical trials for the next 12 months, while also stating it may raise additional funds. No specific revenue or earnings guidance was provided.
- The Phase 1 dose-escalation work and secondary-endpoint trials for IGC-AD1 were reported complete. The company said the drug appeared generally safe and well tolerated, subject to FDA concurrence; this does not establish efficacy. Further trials, funding and regulatory approval are needed.
- Management expects R&D expenses to increase as IGC-AD1 trials progress. It cited uncertainty around trial outcomes, FDA and other regulatory requirements, commercialization, intellectual property, and COVID-19-related operating disruption.
- Shareholder class-action defendants reached a preliminary settlement agreement in principle, subject to final documentation and court approval. The company recorded a $200,000 provision and expected insurance to cover a significant portion. The filing also describes separate Apogee litigation, which the company intends to defend.
- A vendor reported approximately $1.7 million of inventory stolen and filed an insurance claim; the company recorded a provision and said it is pursuing compensation. A separate $376,000 claim receivable from Cochin International Airport is subject to legal collection proceedings, with recovery timing uncertain.
- The company reported disclosure controls and procedures were effective. COVID-19 restrictions, currency movements, litigation, low revenue and reliance on equity financing remain relevant risks.
Important facts for investors to verify
- Whether the reported stolen inventory is recoverable from the vendor or insurer, and the ultimate financial impact.
- Final terms, court approval, insurance coverage and cash cost of the shareholder litigation settlement.
- FDA feedback and complete secondary-endpoint results for IGC-AD1, plus the funding and timeline for subsequent trials.
- Cash burn and financing needs relative to management’s stated 12-month liquidity assessment, including potential dilution under the $75 million ATM program.
- Whether Life Sciences products and Infrastructure activity can generate meaningful, sustainable revenue as pandemic-related disruption eases.